Rafael Fonseca: No one can guarantee outcome, but you can guarantee intent
Rafael Fonseca, Hematologist at Mayo Clinic, shared a post on X:
“When writing treatment orders for induction therapy, frontline transplant-eligible myeloma, this is the correct box to click.
No one can guarantee outcome, but you can guarantee intent.”
Robert Z. Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, also shared a post on X:
“While a noble sentiment, Dara-KRD is neither FDA approved nor listed by NCCN as a category 1 (or even a preferred) regimen (due to a lack of Phase III data).
The counterargument then is that you raise false expectations and put the patient at risk of financial toxicity.”
Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing in multiple myeloma and related conditions. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment. He has led research on genetic markers in myeloma.
Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.
More posts featuring Rafael Fonseca.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023